Qualigen Therapeutics Announces Inclusion in Russell Microcap® Index
June 08 2021 - 7:30AM
Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company
focused on developing novel therapeutics for the treatment of
cancer and viral diseases, announced today that according to a
preliminary list of additions posted June 4 it will be added to the
Russell Microcap Index at the conclusion of the 2021 Russell
indexes annual reconstitution, effective on June 28, 2021.
Membership in the Russell Microcap® Index
means automatic inclusion in the appropriate growth and value
indexes. FTSE Russell determines membership for its indexes
primarily by objective, market-capitalization rankings as well as
style attributes.
“We are excited that Qualigen Therapeutics will
be included in the widely referenced Russell Microcap Index, with
some of the most innovative public companies in the U.S. For
Qualigen, it reflects the company’s progress toward advancing our
promising oncology and viral disease pipeline programs,” stated
Michael Poirier, Chairman and Chief Executive Officer at Qualigen
Therapeutics.
Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. Approximately $10.6
trillion in assets are benchmarked against Russell’s U.S. indexes.
Russell indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell Microcap
Index and the Russell indexes reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
About Qualigen Therapeutics,
Inc.
Qualigen Therapeutics, Inc. is a biotechnology
company focused on developing novel therapeutics for the treatment
of cancer and infectious diseases, as well as maintaining and
expanding its core FDA-approved FastPack® System, which has been
used successfully in diagnostics for 20 years. Our cancer
therapeutics pipeline includes QN-247 (formerly referred to as ALAN
or AS1411-GNP), RAS-F and STARS™. QN-247 is a DNA coated gold
nanoparticle cancer drug candidate that has the potential to target
various types of cancer with minimal side effects; the nanoparticle
coating technology is similar to the core nanoparticle coating
technology used in our blood-testing diagnostic products. The
foundational aptamer of QN-247, QN-165 (formerly referred to as
AS1411), is also a drug candidate for treating COVID-19 and other
viral-based infectious diseases; we currently plan that our first
clinical trial would be a trial of QN-165 against COVID-19. RAS-F
is a family of RAS oncogene protein-protein interaction inhibitor
small molecules for preventing mutated RAS genes' proteins from
binding to their effector proteins; preventing this binding could
stop tumor growth, especially in pancreatic, colorectal and lung
cancers. STARS is a DNA/RNA-based treatment device candidate for
removal from circulating blood of precisely targeted tumor-produced
and viral compounds.
Because Qualigen's therapeutic candidates are
still in the development stage, Qualigen's only products that are
currently commercially available are FastPack System diagnostic
instruments and test kits, used in physician offices, clinics and
small hospitals around the world.
The FastPack System menu includes rapid
point-of-care diagnostic tests for cancer, men's health, hormone
function, and vitamin D status. Qualigen's facility in Carlsbad,
California is FDA and ISO Certified and its FastPack product line
is sold worldwide by its commercial partner Sekisui Diagnostics,
LLC.
For more information on Qualigen Therapeutics,
Inc., please visit https://www.qualigeninc.com.
About FTSE Russell
FTSE Russell is a global index leader that
provides innovative benchmarking, analytics and data solutions for
investors worldwide. FTSE Russell calculates thousands of indexes
that measure and benchmark markets and asset classes in more than
70 countries, covering 98% of the investable market globally.
FTSE Russell index expertise and products are
used extensively by institutional and retail investors globally.
Approximately $17.9 trillion is currently benchmarked to FTSE
Russell indexes. For over 30 years, leading asset owners, asset
managers, ETF providers and investment banks have chosen FTSE
Russell indexes to benchmark their investment performance and
create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE
Russell index design and management: a transparent rules-based
methodology is informed by independent committees of leading market
participants. FTSE Russell is focused on applying the highest
industry standards in index design and governance and embraces the
IOSCO Principles. FTSE Russell is also focused on index innovation
and customer partnerships as it seeks to enhance the breadth, depth
and reach of its offering.
FTSE Russell is wholly owned by London Stock
Exchange Group.
For more information, visit
www.ftserussell.com.
Forward-Looking Statements
This news release contains forward-looking
statements by the Company that involve risks and uncertainties and
reflect the Company's judgment as of the date of this release.
These statements include those related to the Company's prospects
and strategy for the development of therapeutic drug candidates.
Actual events or results may differ from the Company's
expectations. For example, there can be no assurance that clinical
trials will be approved to begin by or will proceed as contemplated
by any projected timeline; that the Company will successfully
develop any drugs or therapeutic devices; that preclinical or
clinical development of the Company's drugs or therapeutic devices
will be successful; that future clinical trial data will be
favorable or that such trials will confirm any improvements over
other products or lack negative impacts; that any drugs or
therapeutic devices will receive required regulatory approvals or
that they will be commercially successful; that patents will issue
on the Company's owned and in-licensed patent applications; that
such patents, if any, and the Company's current owned and
in-licensed patents would prevent competition; that the Company
will be able to procure or earn sufficient working capital to
complete the development, testing and launch of the Company's
prospective therapeutic products; or that the Company will be able
to maintain or expand market demand and/or market share for the
Company's diagnostic products. The Company's stock price could be
harmed if any of the events or trends contemplated by the
forward-looking statements fails to occur or is delayed or if any
actual future event otherwise differs from expectations. Additional
information concerning these and other risk factors affecting the
Company's business (including events beyond the Company's control,
such as epidemics and resulting changes) can be found in the
Company's prior filings with the Securities and Exchange
Commission, available at www.sec.gov. The Company disclaims any
intent or obligation to update these forward-looking statements
beyond the date of this news release, except as required by law.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Investor Relations:
For further information: David KugelmanAtlanta
Capital Partners, LLC(404) 856-9157 or (866) 692-6847 Toll Free -
U.S. & Canadadk@atlcp.com
Tony SchorInvestor Awareness, Inc.(847)
971-0922tony@investorawareness.com
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Apr 2023 to Apr 2024